PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23960782-0	2012	The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.	Semaxinib	37-46	ret proto-oncogene	Homo sapiens	94-118	
16849418-3	2006	OBJECTIVE: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC.	Semaxinib	122-128	ret proto-oncogene	Homo sapiens	158-161	
16849418-3	2006	OBJECTIVE: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC.	Semaxinib	122-128	ret proto-oncogene	Homo sapiens	162-165	
16849418-6	2006	RESULTS: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC(50) of approximately 944 nm for SU5416, 562 nm for SU6668, and 224 nm for SU11248.	Semaxinib	48-54	ret proto-oncogene	Homo sapiens	160-163	
16849418-6	2006	RESULTS: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC(50) of approximately 944 nm for SU5416, 562 nm for SU6668, and 224 nm for SU11248.	Semaxinib	236-242	ret proto-oncogene	Homo sapiens	160-163	
17032739-0	2006	Inhibition of RET tyrosine kinase by SU5416.	Semaxinib	37-43	ret proto-oncogene	Homo sapiens	14-17	
17032739-4	2006	We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells.	Semaxinib	14-20	ret proto-oncogene	Homo sapiens	30-33	
17032739-4	2006	We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells.	Semaxinib	14-20	ret proto-oncogene	Homo sapiens	142-145	
17032739-4	2006	We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells.	Semaxinib	14-20	ret proto-oncogene	Homo sapiens	142-145	
17032739-4	2006	We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells.	Semaxinib	14-20	ret proto-oncogene	Homo sapiens	142-145	
17032739-5	2006	SU5416 inhibited RET-mediated signaling through the extracellular signal regulated kinase (ERK) and JNK pathways.	Semaxinib	0-6	ret proto-oncogene	Homo sapiens	17-20	
11418488-0	2001	Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.	Semaxinib	80-86	ret proto-oncogene	Homo sapiens	45-69	
11418488-1	2001	The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit.	Semaxinib	60-66	ret proto-oncogene	Homo sapiens	19-43	
11418488-1	2001	The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit.	Semaxinib	60-66	ret proto-oncogene	Homo sapiens	45-48	
11418488-6	2001	This is the first report of a stable remission achieved after administration of the RTK inhibitor SU5416 in a patient with AML relapse.	Semaxinib	98-104	ret proto-oncogene	Homo sapiens	84-87